Twist Bioscience: Liquid Biopsy And AI Tailwinds
Source: SeekingAlpha
2026-02-10 02:53:50 ET
Twist Bioscience's ( TWST ) stock has rebounded sharply in recent months, driven by growing optimism around the impact of AI-enabled drug discovery and MRD testing adoption. Twist's Biopharma segment is reaccelerating, driven by AI-enabled drug discovery customers, and NGS growth is expected to rebound as FY27 progresses, driven by MRD customers....
Read the full article on Seeking Alpha
For further details see:
Twist Bioscience: Liquid Biopsy And AI Tailwinds
Twist Bioscience Corporation
NASDAQ: TWST
TWST Trading
-2.1% G/L:
$45.82 Last:
481,655 Volume:
$46.36 Open:
TWST Latest News
February 17, 2026 07:00:00 am
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
February 10, 2026 08:00:00 am
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
TWST Stock Data
$2,986,186,543
59,423,304
2.85%
91
N/A
Medical Diagnostics & Screening
Healthcare
US
South San Francisco
